Cargando…

Identification of transcriptome signature for predicting clinical response to bevacizumab in recurrent glioblastoma

Glioblastomas are among the most fatal brain tumors. Although no effective treatment option is available for recurrent glioblastomas (GBMs), a subset of patients evidently derived clinical benefit from bevacizumab, a monoclonal antibody against vascular endothelial growth factor. We retrospectively...

Descripción completa

Detalles Bibliográficos
Autores principales:	Choi, Seung Won, Shin, Hyemi, Sa, Jason K., Cho, Hee Jin, Koo, Harim, Kong, Doo‐Sik, Seol, Ho Jun, Nam, Do‐Hyun
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	John Wiley and Sons Inc. 2018
Materias:	Clinical Cancer Research
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5943425/ https://www.ncbi.nlm.nih.gov/pubmed/29573206 http://dx.doi.org/10.1002/cam4.1439

Ejemplares similares

Ethnic delineation of primary glioblastoma genome
por: Koo, Harim, et al.
Publicado: (2020)

Multi-Habitat Radiomics Unravels Distinct Phenotypic Subtypes of Glioblastoma with Clinical and Genomic Significance
por: Choi, Seung Won, et al.
Publicado: (2020)

Novel Semi-Replicative Retroviral Vector Mediated Double Suicide Gene Transfer Enhances Antitumor Effects in Patient-Derived Glioblastoma Models
por: Lee, Mijeong, et al.
Publicado: (2019)

Hypermutagenesis in untreated adult gliomas due to inherited mismatch mutations
por: Sa, Jason K., et al.
Publicado: (2019)

CD44 expression in the tumor periphery predicts the responsiveness to bevacizumab in the treatment of recurrent glioblastoma
por: Nishikawa, Masahiro, et al.
Publicado: (2021)

Bevacizumab in recurrent glioblastoma
por: Martinez, Nina L., et al.
Publicado: (2019)

Integrative radiogenomic analysis for genomic signatures in glioblastomas presenting leptomeningeal dissemination
por: You, Hye Jin, et al.
Publicado: (2016)

Analysis of risk factors to predict communicating hydrocephalus following gamma knife radiosurgery for intracranial schwannoma
por: Lee, Seunghoon, et al.
Publicado: (2016)

Effect of Bevacizumab Treatment in Cerebral Radiation Necrosis : Investigation of Response Predictors in a Single-Center Experience
por: Lee, Shin Heon, et al.
Publicado: (2023)

Bevacizumab for the Treatment of Recurrent Glioblastoma
por: Chamberlain, Marc C.
Publicado: (2011)

Clinical benefit in recurrent glioblastoma from adjuvant NovoTTF-100A and TCCC after temozolomide and bevacizumab failure: a preliminary observation
por: Wong, Eric T, et al.
Publicado: (2015)

Quantitative radiomic profiling of glioblastoma represents transcriptomic expression
por: Kong, Doo-Sik, et al.
Publicado: (2018)

Sphere-Forming Culture for Expanding Genetically Distinct Patient-Derived Glioma Stem Cells by Cellular Growth Rate Screening
por: Shin, Kayoung, et al.
Publicado: (2020)

Phase II trial of ponatinib in patients with bevacizumab‐refractory glioblastoma
por: Lee, Eudocia Q., et al.
Publicado: (2019)

Clinical Outcomes of Moderately Hypofractionated Concurrent Chemoradiotherapy for Newly Diagnosed Glioblastoma
por: Kim, Nalee, et al.
Publicado: (2023)

Bevacizumab for Patients with Recurrent Multifocal Glioblastomas
por: Burger, Michael C., et al.
Publicado: (2017)

An ANOCEF Genomic and Transcriptomic Microarray Study of the Response to Irinotecan and Bevacizumab in Recurrent Glioblastomas
por: Laffaire, Julien, et al.
Publicado: (2014)

Pharmacogenomic profiling reveals molecular features of chemotherapy resistance in IDH wild-type primary glioblastoma
por: Nam, Yoonhee, et al.
Publicado: (2023)

Phase II trial of upfront bevacizumab and temozolomide for unresectable or multifocal glioblastoma
por: Lou, Emil, et al.
Publicado: (2013)

Genomic and transcriptomic characterization of skull base chordoma
por: Sa, Jason K., et al.
Publicado: (2016)

Bevacizumab combined with re-irradiation in recurrent glioblastoma
por: She, Lei, et al.
Publicado: (2022)

Mutation-specific non-canonical pathway of PTEN as a distinct therapeutic target for glioblastoma
por: Choi, Seung Won, et al.
Publicado: (2021)

Clinical Targeted Next-Generation sequencing Panels for Detection of Somatic Variants in Gliomas
por: Shin, Hyemi, et al.
Publicado: (2020)

Bevacizumab continuation beyond initial bevacizumab progression among recurrent glioblastoma patients
por: Reardon, D A, et al.
Publicado: (2012)

Glioblastoma endothelium drives bevacizumab‐induced infiltrative growth via modulation of PLXDC1
por: Falchetti, Maria Laura, et al.
Publicado: (2018)

Similar overall survival with reduced vs. standard dose bevacizumab monotherapy in progressive glioblastoma
por: Gleeson, Jack Patrick, et al.
Publicado: (2019)

Bevacizumab Improves Quality of Life in Patients with Recurrent Glioblastoma
por: Nagpal, Seema, et al.
Publicado: (2011)

Safety and efficacy of bevacizumab biosimilar in recurrent/ progressive glioblastoma
por: Kumar, Gunjesh, et al.
Publicado: (2021)

Systematic Review and Network Meta-Analysis of Bevacizumab Plus First-Line Topotecan-Paclitaxel or Cisplatin-Paclitaxel Versus Non–Bevacizumab-Containing Therapies in Persistent, Recurrent, or Metastatic Cervical Cancer
por: Rosen, Virginia M., et al.
Publicado: (2017)

Role of alternative splicing signatures in the prognosis of glioblastoma
por: Xie, Zu‐cheng, et al.
Publicado: (2019)

Bevacizumab for glioblastoma
por: Narita, Yoshitaka
Publicado: (2015)

Glioblastoma recurrence correlates with NLGN3 levels
por: Liu, Rui, et al.
Publicado: (2018)

Re-irradiation combined with bevacizumab for recurrent glioblastoma beyond bevacizumab failure: survival outcomes and prognostic factors
por: You, Weir-Chiang, et al.
Publicado: (2023)

An immune‐related prognostic signature for predicting breast cancer recurrence
por: Tian, Zelin, et al.
Publicado: (2020)

Bevacizumab for the Treatment of Glioblastoma
por: Gil-Gil, Miguel J., et al.
Publicado: (2013)

Therapeutic Efficacy of GC1118, a Novel Anti-EGFR Antibody, against Glioblastoma with High EGFR Amplification in Patient-Derived Xenografts
por: Lee, Kyoungmin, et al.
Publicado: (2020)

Tumor Treating Field Therapy in Combination with Bevacizumab for the Treatment of Recurrent Glioblastoma
por: Omar, Ayman I.
Publicado: (2014)

“Paradoxical” findings of tumor vascularity and oxygenation in recurrent glioblastomas refractory to bevacizumab
por: Yamamoto, Yohei, et al.
Publicado: (2017)

Eosinophil and lymphocyte counts predict bevacizumab response and survival in recurrent glioblastoma
por: Vaios, Eugene J, et al.
Publicado: (2020)

Use of Bevacizumab in recurrent glioblastoma: a scoping review and evidence map
por: Fu, Minjie, et al.
Publicado: (2023)

Cannot write session to /tmp/vufind_sessions/sess_5405fk3q17nnuhfpp3gm6pjvpp